Larotaxel

Cat. No.: IBDI-434908

Larotaxel (XRP9881) is a taxane analogue with preclinical activity against taxane-resistant breast cancer. Larotaxel (XRP9881) exerts its cytotoxic effect by promoting tubulin assembly and stabilizing microtubules, ultimately leading to cell death by apoptosis. It presents the ability to cross the blood brain barrier and has a much lower affinity for P-glycoprotein 1 than Docetaxel.

Product Details

Target	Apoptosis
Molecular Weight	831.90
Appearance	Solid
Synonyms	XRP9881
SMILES	O=C([[email protected]]1([H])OC(C)=O)[[email protected]@]23[[email protected]@]([[email protected]@H]([[email protected]@]4(O)C(C)(C)C1=C([[email protected]](OC([[email protected]](O)[[email protected]](C5=CC=CC=C5)NC(OC(C)(C)C)=O)=O)C4)C)OC(C6=CC=CC=C6)=O)([H])[[email protected]]7([[email protected]@](OC7)([H])C[[email protected]@H]2C3)OC(C)=O
Purity	≥97.0%

Storage & Handling

Shipping	Room temperature in continental US. May vary elsewhere.
Storage	Powder: -20°C/3 years; 4°C/2 years In solvent: -80°C/6 months; -20°C/1 month
Regulatory Status	This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use.